Sign in
RAONF Stock Price, Chart, Stats & News
Race Oncology Limited
Save
Race Oncology Limited (RAONF) does not currently pay a dividend.
451.73M
Market cap
–
Current P/E
–
Forward P/E
RAONF chart
Price history is unavailable
We don't have enough price data for RAONF to draw a chart yet.
About
Health care
Sector
Biotechnology
Industry
Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's primary focus is the development of Zantrene, a potent small molecule designed to inhibit the fatso/fat mass and obesity associated protein (FTO). This therapeutic agent is currently in Phase II/III clinical trials, exploring its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer.
Similar securities
Based on sector and market capitalization
Report issue